CD133 was detected in several types of cancers including hepatocellular carcinoma (HCC), which raised the possibility of stem cell origin in a subset of cancers. However, reappearance of embryonic markers in de-differentiated malignant cells was commonly observed. It remained to be elucidated whether CD133-positive HCCs were indeed of stem cell origin or they were just a group of poorly differentiated cells acquiring an embryonic marker. The aim of this study was to investigate the significance of CD133 expression in HCC in an area endemic for hepatitis B virus (HBV) infection to gain insights on this issue. 154 HCC patients receiving total removal of HCCs were included. 104 of them (67.5%) were positive for HBV infection. The cancerous and adjacent non-cancerous liver tissues were subjected for Western blot and immunohistochemistry analysis for CD133 expression. The data were correlated with clinical parameters, patient survivals, and p53 expression. Of 154 patients, 24 (15.6%) had CD133 expression in HCC. Univariate and multivariate logistic regression analysis revealed that CD133 expression was negatively correlated with the presence of hepatitis B surface antigen (HBsAg). The unadjusted and adjusted odds ratios were 0.337 (95%CI 0.126 - 0.890) and 0.084 (95%CI 0.010 - 0.707), respectively. On the other hand, p53 expression was positively associated with the presence of HBsAg in univariate analysis. The unadjusted odds ratio was 4.203 (95%CI 1.110 - 18.673). Survival analysis indicated that both CD133 and p53 expression in HCC predicted poor disease-free survival (P = 0.009 and 0.001, respectively), whereas only CD133 expression predicted poor overall survival (P = 0.001). Cox proportional hazard model showed that p53 and CD133 expression were two independent predictors for disease-free survival. The hazard ratios were 1.697 (95% CI 1.318 - 2.185) and 2.559 (95% CI 1.519 - 4.313), respectively (P < 0.001 for both). In area where HBV infection accounts for the major attributive risk of HCC, CD133 expression in HCC was negatively associated with the presence of HBsAg, implicating a non-viral origin of CD133-positive HCC. Additionally, CD133 expression predicted poor disease-free survival independently of p53 expression, arguing for two distinguishable hepatocarcinogenesis pathways.
Pancreatic ductal adenocarcinoma (PDA) is notorious for its poor prognosis. The current mainstay of treatment for PDA is surgical resection followed by adjuvant chemotherapy. However, it is difficult to predict the post-operative outcome because of the lack of reliable markers. The single-nucleotide polymorphism (SNP) of N-acetylgalactosaminyltransferase14 (GALNT14) has been proven to predict the progression-free survival (PFS), overall survival (OS) and response to chemotherapy in various types of gastrointestinal (GI) cancers. However, its role in PDA has not been studied. This study aims to investigate whether the GALNT14 SNP genotype can be a prognostic marker for PDA. A cohort of one hundred and three PDA patients having received surgical resection were retrospectively enrolled. GALNT14 genotypes and the clinicopathological parameters were correlated with postoperative prognosis. The genotype analysis revealed that 19.4%, 60.2% and 20.4% of patients had the GALNT14 “TT”, “TG” and “GG” genotypes, respectively. The patients with the “GG” genotype had a mean OS time of 37.1 months (95% confidence interval [CI]: 18.2–56.1) and those with the “non-GG” genotype had a mean OS time of 16.1 months (95% CI: 13.1–19.2). Kaplan–Meier analysis showed that the “GG” genotype had a significantly better OS compared to the “non-GG” genotype (p = 0.005). However, there was no significant difference between the “GG” and “non-GG” genotypes in PFS (p = 0.172). The baseline characteristics between patients with the “GG” and “non-GG” genotypes were compared, and no significant difference was found. Univariate followed by multivariate Cox proportional hazard models demonstrated the GALNT14 “GG” genotype, negative resection margin, and locoregional disease as independent predictors for favorable OS (p = 0.003, p = 0.037, p = 0.021, respectively). Sensitivity analysis was performed in each subgroup to examine the relationship of GALNT14 with different clinicopathological variables and no heterogeneity was found. The GALNT14 “GG” genotype is associated with favorable survival outcome, especially OS, in patients with resected PDA and could serve as a prognostic marker.
19 February 2020 in Advances in Digestive Medicine
Severe gastrointestinal (GI) hemorrhage is a rare initial presentation in Crohn's disease (CD) and poses a therapeutic challenge for clinical care. Currently, there is no conclusive consensus or guideline on the treatment modalities for CD‐related GI bleeding. We present the case of a 21‐year‐old man with acute lower GI bleeding who accepted transcatheter arterial embolization to attain hemostasis. After 1 day of embolization, intractable abdominal pain happened and emergent laparoscopic exploration was arranged. Operation finding reported stenosis and chronic inflammation changes near ileal‐cecal valve. Besides, several bleeding sites and perforation are detected, which is different from splanchnic branch of embolization. Pathology of resected bowel reported transmural acute and chronic inflammation with fibrin and purulent exudates is shown on the serosa. CD is favored. In CD, the most common bleeding site in the literature is located at descending and sigmoid colon. To attain hemostasis, some literature studies raise concerns about embolic‐related complication of intestinal infarction. We would like to share a case of unusual bleeding site and provide consideration of embolization as an option for the treatment of CD.
Crohn's disease (CD) is characterized by chronic and/or relapsing immune activation and inflammation within the gastrointestinal tract. Approximately 35% of patients with CD are complicated by fistulae. However, little is known about the incidence and natural history of fistulizing CD in Asia, especially enterocutaneous fistulae (ECF). In this study, we aimed to investigate the clinical course and outcomes of patients with fistulizing CD. We performed a retrospective analysis using the database of Chang Gung Memorial Hospital to analysis the clinical characteristics, clinical course of CD, gender, age, medical and surgical treatment, complications, and long‐term outcomes. From January 1989 to November 2016, 97 patients were enrolled (73 males and 24 females) with a median age at diagnosis of CD of 32 years (average 36.28 ± 15.84 years). All of the patients were classified by Montreal classification. Montreal classifications A2 (age 16‐40 years; n = 56, 57.7%), L3 (ileocolonic type; n = 47, 48.5%), and B1 (nonstricturing and nonpenetrating type; n = 43, 44.3%) were the most common phenotypes. ECF occurred in five patients (5.1%), enterovaginal fistula in three patients (3.1%), and enterovesical fistula in two patients (2.0%). The duration of CD before the onset of ECF was 3.9 years, enterovaginal fistula was 2.5 years, and enterovesical fistula was 5 years, and most of the patients complicated with a fistula required surgical treatment.